Ascentage Pharma’s Fast-Tracked Bid to Reshape Leukemia Care

ROCKVILLE, Md. – October 20, 2026 — For decades, the operational mechanics of treating chronic lymphocytic leukemia and small lymphocytic lymphoma (CLL/SLL) have resembled a war of attrition. Patients and healthcare systems alike were locked into paradigms of continuous, indefinite therapy. But the strategic aperture of oncology is widening, shifting rapidly toward regimens that offer deep, durable remissions with a fixed endpoint. Today, that shift accelerated.

Ascentage Pharma Group International, a commercial-stage biopharmaceutical company known for its focus on apoptosis-pathway inhibitors, announced that its novel Bcl-2 inhibitor, lisaftoclax (APG-2575), has been granted Breakthrough Therapy Designation (BTD) by the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration. Granted for use in combination with the BTK inhibitor acalabrutinib, this designation targets the treatment-naïve—or frontline—adult patient population with CLL/SLL.

The announcement is more than a regulatory milestone; it is a critical indicator of shifting market dynamics in global hematology. By securing this designation, Ascentage is not merely advancing a clinical asset; it is positioning itself to challenge established monopolies and redefine the economic and operational models of leukemia care in one of the world's largest pharmaceutical markets.

Breaking the Cycle of Continuous Therapy

CLL/SLL is a clonal proliferative malignancy of B lymphocytes that predominantly affects older adults, accounting for more than 100,000 new cases worldwide each year. Historically, the standard of care relied heavily on immunochemotherapy. While effective for some, it presented severe limitations for patients with high-risk genetic features, such as the del(17p) or TP53 mutations.

The introduction of Bruton’s tyrosine kinase (BTK) inhibitors—such as ibrutinib, acalabrutinib, and zanubrutinib—revolutionized the landscape. These targeted therapies offered high response rates and became the bedrock of frontline treatment. However, the operational reality of BTK inhibitor monotherapy is that it requires continuous, lifelong administration. This indefinite treatment cycle introduces significant challenges: cumulative financial toxicity for payers, the psychological burden on patients, the eventual emergence of drug resistance, and a spectrum of long-term adverse events.

"The clinical community has been desperate for a viable exit strategy for these patients," noted one senior oncology researcher familiar with the landscape. "Continuous kinase inhibition suppresses the disease, but it rarely eradicates the minimal residual disease. The goal is to hit the cancer from two different mechanistic angles, achieve an undetectable minimal residual disease state, and then stop the drugs."

This is precisely the strategic gap Ascentage aims to fill. By combining a BTK inhibitor (acalabrutinib) with a selective Bcl-2 inhibitor (lisaftoclax), the regimen attacks the malignancy's survival pathways simultaneously. The BTK inhibitor halts the proliferation of the cancer cells, while the Bcl-2 inhibitor restores the cells' natural apoptotic process, forcing them to die. The ultimate objective is a fixed-duration, chemotherapy-free regimen that allows patients to eventually cease treatment entirely.

Taking Aim at a Global Monopoly

To understand the business implications of Ascentage’s latest move, one must look at the current competitive chessboard. The Bcl-2 inhibitor space has long been dominated by a single player: venetoclax, developed jointly by AbbVie and Roche. As the first-in-class Bcl-2 inhibitor, venetoclax established a virtual monopoly, proving the immense clinical and commercial viability of the mechanism, particularly when combined with obinutuzumab for fixed-duration frontline therapy.

Lisaftoclax is positioned as the second-in-class Bcl-2 inhibitor globally, and notably, the first developed natively in China. Ascentage already secured a critical beachhead in July 2025, when the NMPA approved lisaftoclax for adult patients with CLL/SLL who had previously received at least one systemic therapy, including a BTK inhibitor. Now, the company is aggressively moving up the treatment paradigm into the much larger and more lucrative frontline setting.

The tip of this spear is the GLORA-2 study, a massive global, multi-center, randomized Phase III clinical trial. GLORA-2 is designed to evaluate the efficacy and safety of lisaftoclax in combination with acalabrutinib directly against the established standard of care: venetoclax in combination with obinutuzumab.

Dr. Yifan Zhai, Chief Medical Officer of Ascentage Pharma, emphasized the strategic importance of the regulatory nod. “This BTD recognizes the clinical potential of lisaftoclax in combination with acalabrutinib for patients with treatment-naïve CLL/SLL and the urgent unmet need in this setting,” Zhai stated. “Moving forward, we are continuing to accelerate the global clinical development of lisaftoclax across relevant indications and are striving to bring this treatment to more patients as quickly as possible.”

If GLORA-2 demonstrates comparable or superior efficacy—particularly in achieving undetectable minimal residual disease (uMRD)—alongside a differentiated or more favorable safety profile, Ascentage could disrupt a multi-billion-dollar global franchise.

The Strategic Engine of China’s Regulatory Fast Track

The Breakthrough Therapy Designation is not merely a symbolic accolade; it is a powerful operational accelerant. Modeled similarly to the US FDA’s pathway, China’s CDE grants BTDs to innovative drugs that treat serious, life-threatening conditions where preliminary clinical evidence demonstrates a substantial improvement over existing therapies.

For Ascentage, the practical benefits are profound. BTD status guarantees priority communication and intensive guidance from the CDE throughout the drug's development lifecycle. More crucially, upon submission of a New Drug Application (NDA), the drug becomes eligible for Priority Review and conditional approval. In the complex regulatory environment of China, Priority Review can compress the standard evaluation timeline from years to a matter of months.

"Securing a BTD in China fundamentally alters a company's commercial runway," explained an industry analyst specializing in Asian biopharma markets. "It moves the revenue horizon significantly closer. Furthermore, drugs that pass through these expedited pathways are often viewed favorably when it comes time to negotiate inclusion on the National Reimbursement Drug List."

The National Reimbursement Drug List (NRDL) is the ultimate commercial catalyst in China. Managed by the National Healthcare Security Administration (NHSA), inclusion on the list ensures broad patient access and reimbursement across the country's massive public health infrastructure. While NRDL inclusion typically requires steep price concessions, the resulting volume can transform a biotech firm's balance sheet overnight. Ascentage has already successfully navigated this process with its first approved product, olverembatinib, proving its capability to execute on domestic commercialization.

A Global Chessboard for Biotech Innovation

While the immediate regulatory victory is domestic, Ascentage’s operational aperture is decidedly global. The company’s pipeline strategy illustrates a sophisticated understanding of modern biopharmaceutical growth: leveraging accelerated pathways and early revenue in a massive home market to fund and validate expansive global trials.

In the United States and the European Union, lisaftoclax remains an investigational compound. However, Ascentage has been meticulously laying the groundwork for international expansion. The drug has already received Orphan Drug Designation (ODD) from both the US FDA and the EMA for the treatment of CLL. These designations offer their own suite of strategic advantages, including tax credits, fee waivers, and potential market exclusivity upon approval.

The ongoing GLORA-2 trial is a global registrational study, meaning Ascentage intends to use the data generated not just for Chinese regulators, but to support eventual NDA submissions in the US and Europe. By conducting head-to-head trials against the global standard of care, the company is signaling its intent to compete at the highest levels of the international market.

As the incidence of CLL/SLL continues to rise globally, and as healthcare systems increasingly prioritize therapies that offer both clinical depth and operational finality, the demand for fixed-duration regimens will only intensify. Ascentage Pharma’s ability to secure Breakthrough Therapy Designation for its lisaftoclax combination is a testament to the accelerating pace of domestic innovation in China. More importantly, it serves as a clear indicator that the global monopoly in Bcl-2 inhibition is facing its most credible, fast-moving challenger to date. The mechanics of success in modern oncology require both scientific ingenuity and regulatory agility, and Ascentage appears to be executing on both fronts.